Document is current
Any future updates will be listed below
-
Authors
Wang, Yang
Nie, Jun
Dai, Ling
Hu, Weiheng
Zhang, Jie
Chen, Xiaoling
Ma, Xiangjuan
Tian, Guangming
Han, Jindi
Han, Sen
Wu, Di
Long, Jieran
Zhang, Ziran
Fang, Jian https://orcid.org/0000-0002-3004-9708
-
Funding
Funding for this research was provided by:
Chinese Society of Clinical Oncology - Bristol-Myers Squibb Cancer Immunology Research Fund (Y-BMS2019-010)
- License Information
-
More Information
Article History
Received: 28 December 2020
Accepted: 9 May 2021
First Online: 15 June 2021
Declarations
:
: None of the authors have actual or potential conflicts of interest, including any financial, personal or other relation- ships with other people or organizations that could inappropriately influence this article, to declare.
: All participants provide their written informed consent before their treatment of nivolumab or nivolumab + docetaxel.
: All participants provide their written informed consent before their treatment of nivolumab or nivolumab + docetaxel.
: The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.
